RNA splicing as a therapeutic target in myelodysplastic syndromes DOI Creative Commons

C.-C. Tseng,

Esther A. Obeng

Seminars in Hematology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age 60. MDS patients exhibit peripheral blood cytopenias carry an increased risk disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, ZRSR2) early events identified than 50% cases. These cause aberrant pre-mRNA splicing impact pathophysiology. Emerging evidence shows that factor-mutant cells sensitive perturbations targeting spliceosome, aberrantly spliced and/or their regulated molecular pathways. This review summarizes current therapeutic strategies ongoing efforts for treatment MDS.

Язык: Английский

Corneal endothelial dysfunction treatments: Recent advances in non-invasive treatment strategies DOI Creative Commons
Nataliia Gnyliukh, Rabah Boukherroub, Sabine Szunerits

и другие.

Nano Today, Год журнала: 2025, Номер 63, С. 102740 - 102740

Опубликована: Апрель 4, 2025

Язык: Английский

Процитировано

0
Creation of biomimetic polyethylenimine quantum dots nanocomposites for traceable and targeted DNA delivery DOI
Mingjie Wang,

Guowei Qi,

Jiayu He

и другие.

Journal of Molecular Liquids, Год журнала: 2024, Номер 408, С. 125320 - 125320

Опубликована: Июнь 20, 2024

Язык: Английский

Процитировано

3
RNA splicing as a therapeutic target in myelodysplastic syndromes DOI Creative Commons

C.-C. Tseng,

Esther A. Obeng

Seminars in Hematology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age 60. MDS patients exhibit peripheral blood cytopenias carry an increased risk disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, ZRSR2) early events identified than 50% cases. These cause aberrant pre-mRNA splicing impact pathophysiology. Emerging evidence shows that factor-mutant cells sensitive perturbations targeting spliceosome, aberrantly spliced and/or their regulated molecular pathways. This review summarizes current therapeutic strategies ongoing efforts for treatment MDS.

Язык: Английский

Процитировано

1